Video
Dr. Hafron on the “buzz” surrounding the 2021 LUGPA annual meeting
Author(s):
“The future in bladder cancer [and] prostate cancer is really exploding. The therapeutics are coming faster than we ever thought,” says Jason M. Hafron, MD.
Video Player is loading.
In this video, Jason M. Hafron, MD, discusses the feeling of being back to in-person meetings and what was being talked about at 2021 LUGPA annual meeting. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.
Related Videos
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Jason Hafron, MD, outlines AUA 2025 session on clinical trial recruitment
Related Content
